{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:02:58Z","timestamp":1783191778823,"version":"3.54.6"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12328-025-02201-3","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T04:11:22Z","timestamp":1754712682000},"page":"1033-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severe immune-related adverse event colitis successfully treated with single-dose infliximab in an older adult with hepatocellular carcinoma receiving STRIDE therapy"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-2359","authenticated-orcid":false,"given":"Teppei","family":"Tokumaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Uemora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuta","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaumi","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakizaki","family":"Mototsune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Okabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"issue":"6","key":"2201_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000503254","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo M. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1\/PD-L1 and anti-CTLA-4 antibodies. Liver Cancer. 2019;8(6):413\u201326. https:\/\/doi.org\/10.1159\/000503254.","journal-title":"Liver Cancer"},{"issue":"8","key":"2201_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8): EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"2","key":"2201_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","volume":"72","author":"B Sangro","year":"2020","unstructured":"Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.021.","journal-title":"J Hepatol"},{"issue":"4","key":"2201_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040955","volume":"14","author":"M Allouchery","year":"2022","unstructured":"Allouchery M, Beuvon C, P\u00e9rault-Pochat MC, et al. Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review. Cancers (Basel). 2022;14(4): 955. https:\/\/doi.org\/10.3390\/cancers14040955.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2201_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"key":"2201_CR6","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published November 27, 2017. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"issue":"17","key":"2201_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, National Comprehensive Cancer Network, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2201_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112042","volume":"16","author":"TM Ruli Jr","year":"2024","unstructured":"Ruli TM Jr, Pollack ED, Lodh A, et al. Immune checkpoint inhibitors in hepatocellular carcinoma and their hepatic-related side effects: a review. Cancers (Basel). 2024;16(11): 2042. https:\/\/doi.org\/10.3390\/cancers16112042.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2201_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00262-021-03115-y","volume":"71","author":"W Wang","year":"2022","unstructured":"Wang W, Gu X, Wang L, et al. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunol Immunother. 2022;71(7):1693\u2013703. https:\/\/doi.org\/10.1007\/s00262-021-03115-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2201_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020;19(4):479\u201388. https:\/\/doi.org\/10.1080\/14740338.2020.1738382.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"2201_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.7150\/jca.84261","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Shatila M, Mathew A, et al. Role of C-reactive protein in predicting the severity and response of immune-mediated diarrhea and colitis in patients with cancer. J Cancer. 2023;14(10):1913\u20139. https:\/\/doi.org\/10.7150\/jca.84261.","journal-title":"J Cancer"}],"updated-by":[{"DOI":"10.1007\/s12328-025-02212-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000}}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02201-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:46:31Z","timestamp":1763559991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02201-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2201"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02201-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12328-025-02212-0","URL":"https:\/\/doi.org\/10.1007\/s12328-025-02212-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient provided informed consent for the publication of this case report, and the study was approved by the ethics committee of our institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the research protocol"}}]}}